A clinical stage, biopharmaceutical company, focused on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases, Angion Biomedica Corporation (NASDAQ:ANGN) has been active in the SBIR space since soon after its founding in 1998. Having gone public in February 2021, the company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. With an emphasis on addressing the need for therapeutics in orphan and clinical markets of unmet medical needs in acute tissue injury, fibrosis, and cancer, products include BB3, a HGF mimetic product for renal transplantation (acute), myocardial infarction (acute), hepatic fibrosis (chronic), and stroke, other products also under development aANG-3070 tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was incorporated in 1998 and is based in Uniondale, New York with additional offices in San Francisco, California and Newton, Massachusetts.
